Lupin moves up as its arm launches Propranolol LA capsules
Lupin is currently trading at Rs. 1106.00, up by 8.95 points or 0.82% from its previous closing of Rs. 1097.05 on the BSE.
The scrip opened at Rs. 1118.15 and has touched a high and low of Rs. 1118.15 and Rs. 1103.60 respectively. So far 4648 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1143.70 on 17-Aug-2023 and a 52 week low of Rs. 623.20 on 19-Sep-2022.
Last one week high and low of the scrip stood at Rs. 1119.95 and Rs. 1066.05 respectively. The current market cap of the company is Rs. 49938.81 crore.
The promoters holding in the company stood at 47.07%, while Institutions and Non-Institutions held 43.30% and 9.64% respectively.
Lupin’s wholly-owned subsidiary -- Lupin Pharma Canada has launched of Propranolol LA (long-acting) capsules, 60 mg, 80 mg, 120 mg and 160 mg, in Canada. Propranolol LA is a generic equivalent of Inderal LA, it provides an effective treatment solution since the discontinuation of Inderal LA for patients and healthcare practitioners. Propranolol LA’s launch caters to the needs of Canadian patients, reaffirming Lupin's commitment to enhancing healthcare access and affordability.
The launch of Propranolol LA, the sole extended-release formulation of Propranolol accessible to Canadian patients following the discontinuation of Inderal LA, has led to significant progress in fulfilling patient unmet needs. This extended-release variant not only ensures consistent alleviation of symptoms but also enhances patient adherence and overall quality of life.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
